Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Iovance Biotherapeutics, Inc. - Common Stock
(NQ:
IOVA
)
8.170
+0.160 (+2.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 31, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Iovance Biotherapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
August 21, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance (IOVA) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
Record Amtagvi revenue and gross margins signal strong commercial momentum in cell therapy.
Via
The Motley Fool
Topics
Earnings
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?
↗
August 10, 2026
The healthcare stock is now up more than 130% this year.
Via
The Motley Fool
Iovance Biotherapeutics (NASDAQ:IOVA) Beats Q2 Estimates on Record Revenue, Shares Jump
↗
August 06, 2026
Via
Chartmill
IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) Passes Mark Minervini’s Trend Template and High-Growth Momentum Screen
↗
June 29, 2026
Via
Chartmill
Iovance Biotherapeutics (NASDAQ:IOVA) Reports Q1 Revenue Beat and Raised Guidance, Yet Stock Slips Pre-Market
↗
May 07, 2026
Via
Chartmill
Iovance Biotherapeutics Q2 Earnings Call Highlights
↗
August 06, 2026
Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded...
Via
MarketBeat
Topics
Earnings
Top stock movements in today's session.
↗
August 06, 2026
Via
Chartmill
Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results
↗
August 06, 2026
Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares are surging Thursday after the cancer therapy company shattered second-quarter expectations on both the top and bottom lines. Here's what you should...
Via
Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
August 06, 2026
Via
Chartmill
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
August 06, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
July 30, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 17, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
This Stock Is Up 74% This Year: Is It Too Late to Buy?
↗
July 08, 2026
The biotech is clearly innovative, but sometimes that's not enough.
Via
The Motley Fool
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
↗
July 04, 2026
Heartflow scales AI diagnostics while Iovance drives personalized cancer therapies, each faces unique financial and operational risks in 2026.
Via
The Motley Fool
Topics
Artificial Intelligence
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
↗
June 23, 2026
Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds.
Via
The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
June 19, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
June 08, 2026
From
Biotech Insider
Via
GlobeNewswire
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
June 03, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For?
↗
June 02, 2026
Tread carefully, but certain factors make this speculative biotech play stand out.
Via
The Motley Fool
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances Delivery-Focused Oncology Platform Amid Growing Interest in Drug-Delivery Technologies
June 01, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
June 01, 2026
Via
Investor Brand Network
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
June 01, 2026
From
BioMedWire
Via
GlobeNewswire
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
June 01, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
May 22, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Present at Upcoming Conference
May 21, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance (IOVA) Q1 2026 Earnings Transcript
↗
May 08, 2026
Iovance (IOVA) Q1 2026 Earnings Transcript
Via
The Motley Fool
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
May 07, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street
↗
May 02, 2026
It could just as well drop by 50% -- or more -- over the next 12 months.
Via
The Motley Fool
Topics
Death
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
April 27, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.